Blood Eicosapentaenoic and Docosahexaenoic Acids Predict All-Cause Mortality in Patients With Stable Coronary Heart Disease

The Heart and Soul Study

James V. Pottala, MS; Sachin Garg, MD; Beth E. Cohen, MD, MAS; Mary A. Whooley, MD; William S. Harris, PhD

Background—Omega-3 fatty acid (n-3 FA) blood levels and intake have been inversely associated with risk for sudden cardiac death, but their relationship with all-cause mortality is unclear. The purpose of this study was to determine the extent to which baseline blood n-3 FA levels are associated with reduced risk for all-cause mortality in patients with stable coronary heart disease.

Methods and Results—The Heart and Soul study used a prospective cohort design with a median follow-up of 5.9 years. Patients were recruited between 2000 and 2002 from 12 outpatient facilities in the San Francisco Bay Area. Standard cardiovascular risk factors, demographics, socioeconomic status, health behaviors, and inflammatory markers were collected at baseline. Fasting blood levels of eicosapentaenoic and docosahexaenoic acids were measured and expressed as a percent of total blood FAs. Vital status was assessed with annual telephone interviews and confirmed by review of death certificates. There were 237 deaths among 956 patients. Cox proportional hazards models were used to evaluate the extent to which blood eicosapentaenoic and docosahexaenoic acids were independently associated with all-cause mortality. Compared with patients having baseline eicosapentaenoic and docosahexaenoic acids levels below the median (less than 3.6%), those at or above the median had a 27% decreased risk of death (hazard ratio, 0.73; 95% confidence interval, 0.56–0.94). This association was unaffected by adjustment for age, sex, ethnicity, center, socioeconomic status, traditional cardiovascular risk factors, and inflammatory markers (hazard ratio, 0.74; 95% confidence interval, 0.55–1.00, P<0.05).

Conclusions—In these outpatients with stable coronary heart disease, blood n-3 FA levels were inversely associated with total mortality independent of standard and emerging risk factors, suggesting that reduced tissue n-3 FA levels may adversely impact metabolism. (Circ Cardiovasc Qual Outcomes. 2010;3:406-412.)

Key Words: coronary heart disease ■ total mortality ■ whole blood ■ eicosapentaenoic acid ■ docosahexaenoic acid ■ biomarker ■ epidemiology

Multiple lines of evidence (epidemiological, mechanistic, and clinical trial) support the view that the long-chain omega-3 fatty acids (n-3 FAs) eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively) reduce the risk for death from coronary heart disease (CHD).1–3 N-3 FAs are polyunsaturated fats that must be obtained from the diet. Lower red blood cell levels of EPA+DHA have been found in patients with acute coronary syndrome4 and primary cardiac arrest.4 In prospective studies, n-3 FA levels were also independently associated with risk for CHD events and CHD mortality.5,6 Given this prior research, red blood cell levels of EPA+DHA have been proposed as a marker for cardiovascular health and risk of fatal CHD.7 Two randomized controlled trials of n-3 FA supplementation, one in survivors of acute myocardial infarction8 and the other in patients with heart failure,9 found that treatment significantly reduced all-cause mortality. However, observational studies based on estimated fish or n-3 FA intakes have yielded conflicting results regarding overall mortality,10–19 but these were not conducted in patients with established CHD in whom an n-3 FA deficit would be expected to have a significant impact on health. In addition, the use of diet questionnaires instead of biomarkers to assess n-3 FA exposure may partly explain the failure to observe significant associations in some studies.

In the present study, we measured blood levels of EPA+DHA and assessed vital status in a prospective cohort...
of 956 ethnically diverse adults with CHD. We hypothesized that higher levels of EPA+DHA would be associated with decreased mortality after adjusting for standard cardiovascular risk factors, demographics, and lifestyle factors.

WHAT IS KNOWN

• Populations that report higher intakes of long-chain omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids) have lower rates of heart disease death than those with lower intakes.
• Supplementation with omega-3 fatty acids has reduced risk for total mortality in high-risk populations.
• Blood levels of omega-3 fatty acids are reliable surrogates of tissue levels, but are only moderately correlated with dietary intakes of these fatty acids.

WHAT THE STUDY ADDS

• Patients with coronary heart disease with above-average blood levels of omega-3 fatty acids are at lower risk for death from any cause than patients with lower levels.
• A reduced blood omega-3 level is an independent risk marker for death from any cause in patients with stable coronary heart disease.

Methods

Participants

As described previously,20 participants were recruited from 2 Department of Veterans Affairs Medical Centers (San Francisco VA Medical Center and the Veterans Affairs Palo Alto Health Care System), 1 university medical center (University of California, San Francisco, UCSF), and 9 public health clinics in the Community Health Network of San Francisco. Patients were eligible for the study if they met at least 1 of the following inclusion criteria: (1) history of myocardial infarction; (2) angiographic evidence of exercise-induced ischemia by treadmill or nuclear testing; or (4) history of coronary revascularization. Participants were excluded if they had had an acute coronary syndrome in the prior 6 months, were not able to walk 1 block, or were likely to move out of the area within 3 years. Between September 2000 and December 2002, a total of 1024 individuals enrolled.

The study protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent. Participants underwent a day-long baseline study appointment that included a medical history interview, a physical examination, and a comprehensive health status questionnaire. Before the baseline visit, study participants refrained from smoking for 5 hours, did not take aspirin for 1 week, and completed an overnight 12-hour fast (except for prescribed medications taken with water). Fasting venous blood samples were drawn, and serum and whole blood were frozen at −70°C. Participants for whom frozen blood was not available (n=37) were excluded and 5 subjects were lost to follow-up. For consistency across types of analyses, all subjects missing on 1 or more confounding variables were eliminated (n=26), resulting in a sample size of 956 participants for this study. Mortality was similar between the 68 excluded patients and the 956 in the analysis (22% and 25%, respectively; P=0.65). The excluded patients were also similar in age, sex, and race (minimum P=0.17). Of note, the excluded patients were more likely to be from a Veterans Affairs Medical Center (P=0.002) because we started our recruitment at the VA and did not have the blood draw protocol up and running for the first 35 patients who enrolled.

Predictors: EPA+DHA Levels

Levels of EPA+DHA in whole blood were measured by capillary gas chromatography as previously described21 and are expressed as a percent of total blood fatty acids. Two erythrocyte control pools were included with each batch to monitor analytic performance. The intra-assay coefficient of variation in the control sample included in each batch was 5.5% for EPA+DHA.

Outcomes: Vital Status

Annual telephone interviews were conducted with participants or their proxies to ask about vital status. All reported deaths were confirmed by review of death certificates, which determined event date for analyses. Censoring was defined as time to death or last follow-up.

Other Variables

Age, sex, ethnicity, medical history, household income, education level, and history of tobacco use were collected by self-report on baseline questionnaires. Household income and education level were included as measures of socioeconomic status, which affects dietary intake of n-3 FAs.21 Medical centers were grouped as Veterans Affairs, university medical center, or health clinic. Categories for ethnicity were Hispanic, Asian, white, African American, or other. Annual household income was grouped as <$10K, $10K to <$20K, $20K to <$40K, and >$40K. Education level was divided into 4 categories: <12th grade, high school graduate or equivalent, some college, or completing a 4-year degree or higher. Body mass index was calculated from height and weight at the baseline visit. During their baseline visit, participants were asked how physically active they had been the previous month. Participants selected “not at all,” “a little,” “fairly,” “quite,” “very,” or “extremely” active; “fairly and quite” were grouped together as were “very or extremely.” All current medications were collected by inspection of prescriptions brought to the baseline visit. Fasting serum samples were used to measure total cholesterol, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor α-α, as previously reported.22 All patients underwent complete resting 2-dimensional echocardiography and Doppler examination using an Acuson Sequoia ultrasound system (Siemens Medical Solutions, Mountain View, Calif) with a 3.5-MHz transducer. Standard parasternal short-axis and apical 2- and 4-chamber views were obtained and planimetered to determine end-diastolic and end-systolic volumes. The left ventricular ejection fraction (LVEF) was calculated as (end-diastolic volume−end-systolic volume)/end-diastolic volume.

Statistical Analyses

Differences in baseline characteristics were evaluated using Wilcoxon rank-sum test and χ2 test for continuous and categorical data, respectively. To test the association between blood EPA+DHA levels and all-cause mortality, Kaplan-Meier, and Cox proportional hazards regression models were developed. Unadjusted differences in Kaplan-Meier estimated survival functions were tested using the log-rank statistic. Log-transformed confidence intervals were calculated for the 75th survival percentile using the method developed by Brookmeyer and Crowley.23 The unadjusted model was followed by the sequential addition of potential confounders, including demographics, socioeconomic status, smoking, LVEF, history of hypertension, diabetes, body mass index, statin and aspirin use, and physical activity. The final model involved the addition of potential mediators, including lipids and inflammatory markers.

Nonlinear relationships between confounding variables and outcome were examined using Martingale residuals that estimate the
Table 1. Characteristics of CAD Patients (n=956) Grouped by Median Blood EPA+DHA Values (as Percentage of Total FAs)

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Below Median &lt;3.6% (n=478)</th>
<th>Above Median ≥3.6% (n=478)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sex, male</td>
<td>65 (57, 73)‡</td>
<td>69 (61, 77)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hispanic</td>
<td>62 (13) 21 (4.4)</td>
<td>65 (14) 24 (4.8)</td>
<td>0.87</td>
</tr>
<tr>
<td>White</td>
<td>280 (59) 298 (62)</td>
<td>294 (62) 318 (66)</td>
<td>0.01</td>
</tr>
<tr>
<td>African American</td>
<td>95 (20) 57 (12)</td>
<td>98 (20) 60 (13)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Asian</td>
<td>25 (5.2) 86 (18)</td>
<td>30 (5.2) 97 (18)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Other</td>
<td>16 (3.3) 16 (3.3)</td>
<td>16 (3.3) 16 (3.3)</td>
<td>0.99</td>
</tr>
<tr>
<td>Medical center</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Veterans Affairs</td>
<td>215 (45) 181 (38)</td>
<td>217 (47) 197 (39)</td>
<td>0.87</td>
</tr>
<tr>
<td>University</td>
<td>116 (24) 212 (44)</td>
<td>121 (26) 221 (45)</td>
<td>0.53</td>
</tr>
<tr>
<td>Public health clinics</td>
<td>147 (31) 85 (18)</td>
<td>150 (32) 82 (18)</td>
<td>0.87</td>
</tr>
<tr>
<td>Household income</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Under $10 000</td>
<td>147 (31) 89 (19)</td>
<td>153 (32) 103 (22)</td>
<td>0.0001</td>
</tr>
<tr>
<td>$10 000 to &lt;$20 000</td>
<td>126 (26) 103 (22)</td>
<td>130 (26) 115 (24)</td>
<td>0.28</td>
</tr>
<tr>
<td>$20 000 to &lt;$40 000</td>
<td>106 (22) 115 (24)</td>
<td>112 (24) 123 (26)</td>
<td>0.60</td>
</tr>
<tr>
<td>&gt;$40 000</td>
<td>103 (22) 171 (36)</td>
<td>109 (22) 177 (37)</td>
<td>0.42</td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Never</td>
<td>113 (24) 173 (36)</td>
<td>119 (26) 179 (38)</td>
<td>0.01</td>
</tr>
<tr>
<td>Past</td>
<td>229 (48) 253 (53)</td>
<td>235 (48) 258 (55)</td>
<td>0.15</td>
</tr>
<tr>
<td>Current</td>
<td>136 (29) 52 (11)</td>
<td>146 (29) 51 (11)</td>
<td>0.73</td>
</tr>
<tr>
<td>Left ventricular ejection fraction, %</td>
<td>63 (57, 67) 64 (59, 68)</td>
<td>64 (57, 65) 64 (57, 65)</td>
<td>0.004</td>
</tr>
<tr>
<td>Diabetes</td>
<td>153 (32) 101 (21)</td>
<td>156 (33) 103 (21)</td>
<td>0.0001</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>361 (75.5) 318 (67)</td>
<td>365 (78) 321 (65)</td>
<td>0.002</td>
</tr>
<tr>
<td>Physically activity</td>
<td></td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Not at all</td>
<td>98 (21) 86 (18)</td>
<td>101 (21) 90 (18)</td>
<td>0.17</td>
</tr>
<tr>
<td>A little</td>
<td>98 (21) 75 (16)</td>
<td>102 (21) 79 (16)</td>
<td>0.13</td>
</tr>
<tr>
<td>Fairly or quite</td>
<td>148 (31) 137 (29)</td>
<td>150 (31) 140 (29)</td>
<td>0.62</td>
</tr>
<tr>
<td>Very or extremely</td>
<td>134 (28) 180 (38)</td>
<td>138 (28) 178 (38)</td>
<td>0.45</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>28 (25, 32) 27 (25, 30)</td>
<td>28 (25, 32) 27 (25, 30)</td>
<td>0.07</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin use</td>
<td>293 (61) 325 (68)</td>
<td>294 (61) 326 (68)</td>
<td>0.03</td>
</tr>
<tr>
<td>Aspirin use</td>
<td>374 (78) 371 (78)</td>
<td>376 (78) 372 (78)</td>
<td>0.82</td>
</tr>
<tr>
<td>Lipids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA+DHA, % of total FA</td>
<td>2.8 (2.3, 3.2) 4.9 (4.1, 6.6)</td>
<td>3.2 (2.8, 3.6) 5.3 (5.0, 5.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L§</td>
<td>1.1 (0.9, 1.3) 1.2 (1.0, 1.4)</td>
<td>1.2 (1.1, 1.3) 1.3 (1.2, 1.3)</td>
<td>0.0002</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L§</td>
<td>4.6 (4.0, 5.4) 4.3 (3.8, 5.0)</td>
<td>4.7 (4.2, 5.2) 4.4 (3.9, 4.9)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Triglyceride, mmol/L§</td>
<td>1.4 (0.9, 2.2) 1.1 (0.8, 1.5)</td>
<td>1.5 (1.0, 2.1) 1.2 (0.9, 1.5)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Wilcoxon rank-sum test for continuous variables; χ² test for categorical variables.
†Median (interquartile range).
‡n (%).
§For cholesterol, convert from mmol/L to mg/dL by multiplying ×38.6; for triglycerides, by 88.5.

Results

The final cohort of 956 patients comprised 396 from VA Medical Centers, 232 from public health clinics, and 328 from the UCSF Medical Center. Median follow-up was 5.9 years (interquartile range, 4.5 to 6.0 years), during which 237 (25%) participants died. The whole-blood EPA+DHA was higher in those who survived than in those who did not (geometric means, 3.8% versus 3.6%, P=0.05). To evaluate a dose response in EPA+DHA, the unadjusted death rates were examined by quartiles. There was no significant difference between quartile 1 (26.4%) and quartile 2 (29.7%) of EPA+DHA (P=0.42, 2-proportion Z-test), nor between quartile 3 (20.1%) and quartile 4 (22.9%) (P=0.45). In other words, death rates exhibited a step function, not a gradient, and therefore the 2 lower and upper quartiles were each combined (difference P=0.02).

All 956 participants were therefore grouped by the median EPA+DHA level (at or above versus below 3.6%; Table 1). Compared with participants below the median, those at or above the median were older, less likely to be African American or Hispanic, and more likely to be Asian and of higher socioeconomic status. Participants above the median also had a more favorable cardiovascular risk profile (eg, higher HDL cholesterol and lower total cholesterol, triglyceride, C-reactive protein, and interleukin-6 levels; a lower prevalence of smoking and diabetes; and were more likely to be very or extremely physically active).
The hazard ratio for those at or above the median level (adjusted for age, sex, ethnicity, and medical center) was reduced by 39% for all-cause deaths ($P<0.0001$, Table 2, Model 1). After further adjustment for potential confounders and mediators, the relative risk reduction ranged from 26% to 31%, and the effect remained significant ($P<0.05$) throughout all covariate models (Table 2, Models 2 to 4). In the fully adjusted model and independent of EPA+DHA, other highly significant relations with total mortality were observed for increasing age and interleukin-6 (directly) and higher LVEF and statin use (inversely; Table 3). Using median blood EPA+DHA categories, Kaplan-Meier–estimated survival curves demonstrated a significant difference in time to death (Figure; log-rank $P=0.02$). Time to 25% mortality was 5.1 years (95% confidence interval, 4.7–6.2) and 6.3 years (95% confidence interval, 5.9–6.9) in those participants whose blood EPA+DHA were below and at or above the median, respectively.

To determine if other FAs could be influencing the differences in mortality associated with levels of EPA+DHA, we substituted several other fatty acids for EPA+DHA in a univariate Cox model. EPA and DHA individually had significant inverse associations with all-cause mortality; additionally C18:1 $\text{trans}$ and C18:2$\text{trans}$ had significant direct associations (Table 4). Each of the individual fatty acids remained significant when adjusted for demographics included in Model 1. Only EPA was significant after further adjustment for LVEF, risk markers, and socioeconomic factors found in Model 2. However, the effect of EPA was attenuated when lipids from Model 3 were included. Both $\text{trans}$ fats (the only other fatty acids that showed univariate relations with total mortality) and their interaction terms with the median EPA+DHA were included in the final Model 4 to test for moderating relationships. The median level of EPA+DHA (at or above versus below 3.6%) remained significant ($P=0.04$), but the $\text{trans}$ fats did not (minimum $P=0.22$).

### Discussion
In patients with stable CHD, we found that higher baseline blood levels of EPA+DHA were associated with an increase in survival time. These findings were independent of traditional cardiovascular risk factors, serum lipids, and of inflammatory markers, and they harmonize with our recent obser-
vation that in this same cohort, the rate of telomeric shortening (a surrogate for cellular aging) was inversely and independently related to blood EPA + DHA levels.26 Although it was not the purpose of this study to formally evaluate the prognostic value of blood n-3 FA levels with respect to total mortality, we were able to gain some insights that may be used in future studies with that goal. Based on a review of the literature, a red blood cell (RBC) EPA + DHA level of 4% had originally been proposed,2,27 as segregating intermediate from high-risk patients. This value found some support in a subsequent cross-sectional analysis.3 In the current study, RBCs were not available, only whole blood. Fortunately, with our method there is a very strong correlation (R=0.96, P<0.0001; unpublished findings) between the EPA + DHA content of RBCs and whole blood, and both metrics have been associated with risk of CHD events, including primary cardiac arrest and sudden cardiac death.4 Converting the median whole blood EPA + DHA value observed in our study of 3.6% to the RBC-based equivalent gave an n-3 index median value of 4.6%, not far from the originally proposed 4%. Although these results suggest that there may be a threshold above which little additional risk reduction may be expected, a very low risk value (previously proposed as 8%) could not be evaluated in the present study, owing to the very few patients who had levels this high.

The relations between the intake of long-chain n-3 FA and all-cause mortality (as opposed to cardiovascular) have been described in many different study populations but are inconsistent. Based on estimated fish or n-3 consumption, 4 studies found significant inverse associations with mortality,10-13 whereas 8 studies did not.10,11,14-18 A 5-year follow-up of 415 Swedish CHD patients28 reported a trend (P=0.06) for reduced total mortality associated with increasing fish intake but no relations with CHD mortality (P=0.73). Positive findings on total mortality and n-3 FAs from prospective cohort studies from China,29 Japan,11 and Korea30 (regions where CHD is not the major cause of death) harmonize with our findings. In a recent report from Norway, elderly, hospitalized patients (mean age, 82 years) with serum phospholipid EPA levels in the lowest quartile were at twice the risk for death over 3 years compared with those subjects in the 3 higher quartiles.31 Higher RBC EPA and DHA levels in centenarians compared with elderly (61 to 99 years of age) control subjects also support the beneficial effect of higher n-3 levels on total mortality. Anderson et al33 reported that reduced plasma EPA levels were associated with greater 20-year mortality in a mixed ethnic population in London. Finally, in a meta-analysis of the effects of dietary and pharmacological treatments for dyslipidemia, total mortality was reduced by only 2 agents: n-3 fatty acids and statins.34

Some of the conflicting findings from other prospective cohort studies may stem from the use of dietary questionnaires, which may not provide accurate estimates of n-3 FA exposure.35 Even if intake could be precisely determined, direct measurement of blood levels of EPA + DHA provides information on interindividual differences in FA metabolism that diet assessments cannot capture. We recently reported that nonfried fish consumption explained only 37% of the variability in the n-3 index,36 and when combined with information on fish oil supplementation, only 47% of the variation was explained.37 In addition to dietary intake, it has been suggested that genetic factors may play a role in establishing blood EPA and DHA content. One single nucleotide polymorphism (rs3834458) in the promoter region of the gene encoding Δ-6 desaturase (the enzyme that controls the conversion of α-linolenic acid to EPA) is associated with lower plasma and adipose EPA levels.38 This polymorphism explains about 5% of the variability in plasma phospholipid

Table 4. Univariate Analysis of Individual FAs (as Percentage of Total FAs) With All-Cause Mortality: Estimates (95% Confidence Intervals) Are per 1% Absolute Increase

<table>
<thead>
<tr>
<th>Fatty Acid</th>
<th>(n=719) Lived Mean (SD)</th>
<th>(n=237) Died Mean (SD)</th>
<th>Unadjusted Cox PH Regression Estimate (95% Confidence Intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C18:1 trans–Elaidic</td>
<td>1.33 (0.60)</td>
<td>1.51 (0.71)</td>
<td>1.38 (1.15–1.65)</td>
</tr>
<tr>
<td>C18:2n6–trans–</td>
<td>0.69 (0.26)</td>
<td>0.76 (0.30)</td>
<td>1.69 (1.18–2.43)</td>
</tr>
<tr>
<td>C18:2n6–Linoleic</td>
<td>22.96 (3.61)</td>
<td>23.22 (3.59)</td>
<td>1.02 (0.98–1.06)</td>
</tr>
<tr>
<td>C20:4n6–Arachidonic</td>
<td>11.83 (2.28)</td>
<td>11.57 (2.33)</td>
<td>0.95 (0.90–1.01)</td>
</tr>
<tr>
<td>C18:3n3–α-Linolenic</td>
<td>0.50 (0.22)</td>
<td>0.49 (0.25)</td>
<td>0.90 (0.51–1.58)</td>
</tr>
<tr>
<td>C20:5n3–Eicosapentaenoic</td>
<td>0.93 (0.88)</td>
<td>0.80 (0.76)</td>
<td>0.81 (0.66–0.98)</td>
</tr>
<tr>
<td>C22:5n3–Docosapentaenoic</td>
<td>1.24 (0.29)</td>
<td>1.22 (0.29)</td>
<td>0.72 (0.46–1.13)</td>
</tr>
<tr>
<td>C22:6n3–Docosahexaenoic</td>
<td>3.30 (1.36)</td>
<td>3.13 (1.23)</td>
<td>0.91 (0.82–1.00)</td>
</tr>
</tbody>
</table>
EPA levels. Because only about half of the variability in the blood n-3 FA levels can be explained by known factors, the estimation of n-3 FA exposure is best performed by direct blood measurement.

Increased n-3 FA levels may decrease mortality through a variety of mechanisms. In prior studies, increased intakes of n-3 FAs have been reported to reduce heart rate, inhibit platelet function, and, at high doses, to reduce serum triglyceride and inflammatory marker levels. These factors may contribute to an observed increase in plaque stability and to a reduced risk for arrhythmias and death from heart failure. These FAs also modulate a wide variety of fundamental physiological functions. At the cellular level, they affect cell signaling, alter membrane composition, and modulate the behavior of ion channels. This can lead to changes in several biological systems, for example, alterations in immune function via interleukin signaling and prevention of apoptosis. n-3 FAs are also converted into a variety of eicosanoids, such as prostaglandins, leukotrienes, prostaoyclins, thromboxanes, and neuroprotections. These substances, in turn, mediate inflammation, vasoconstriction, and platelet aggregation. In our model 4, adjustment for inflammatory biomarkers attenuated (but did not eliminate) the association between EPA + DHA levels and total mortality, suggesting the beneficial effects of n-3 fatty acids may be partially mediated by a reduction in systemic inflammation.

Our findings suggest that testing for blood EPA + DHA levels may have clinical utility. Unlike several other risk factors that cannot be easily modified, the level of EPA + DHA in the blood can be raised by increased consumption of these fatty acids in either oily fish (salmon, mackerel, herring, sardines, albacore tuna, etc) or in fish oil supplements. Both approaches are safe and inexpensive, and, importantly, have been shown to reduce total mortality in randomized trials.

There are several strengths of this study, including a large and rigorously defined sample, detailed FA analysis, the inclusion of plasma lipid and inflammatory covariates, a racially diverse sample, and an unambiguous end point. There were also several limitations. This was an observational study and thus unmeasured confounding factors may have contributed to our findings. The cohort was mostly older men, all with known CHD, and thus our results may not be generalizable to younger or female patients, or those without CHD. In addition, we measured blood levels of n-3 FAs at one point in time, and levels may have fluctuated during the follow-up period. Finally, without detailed dietary analyses, we were unable to determine the extent to which low n-3 FA intakes (versus differences in metabolism) were the cause of the low EPA + DHA in those at highest risk for death, although as noted above, only about half of the variability in this marker can be explained by dietary differences.

**Conclusion**

A reduced blood EPA + DHA level is independently related to risk for death in patients with CHD. These findings suggest that EPA + DHA tissue levels may be playing an optimizing role in normal cellular metabolism, which, if not provided, leads to premature death. Further studies are needed in larger and more diverse populations to more clearly define the utility of blood EPA + DHA in risk prediction and to determine risk threshold levels over a wider range of values.

**Acknowledgments**

Nonauthors who have made substantial contributions to this work include Brenda Collison-Schmidt, BA, and Andrew Christianson, BS, both from Sanford Research/USD, for conducting the blood fatty acid analysis. They received no additional compensation for this work.

**Sources of Funding**

The Heart and Soul study was funded by the VA Epidemiology (Merit Review) Program; the VA Health Services Research and Development service Career Development Program; the National Heart Lung and Blood Institute (RO1 HL079235); the American Federation for Aging Research (Paul Beeson Scholars Program); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); the Ischemia Research and Education Foundation; and the Nancy Kirwan Heart Research Fund. The funding organizations had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

**Disclosures**

Dr Harris is a scientific advisor to the following companies with interests in n-3 FAs: Monsanto Company, GlaxoSmithKline, Acasti Pharma, Neptune, and Unilever. He is also the founder and owner of OmegaQuant, LLC, a company that offers blood fatty acid testing.

**References**


Blood Eicosapentaenoic and Docosahexaenoic Acids Predict All-Cause Mortality in Patients With Stable Coronary Heart Disease: The Heart and Soul Study
James V. Pottala, Sachin Garg, Beth E. Cohen, Mary A. Whooley and William S. Harris

Circ Cardiovasc Qual Outcomes. 2010;3:406-412; originally published online June 15, 2010; doi: 10.1161/CIRCOUTCOMES.109.896159
Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circoutcomes.ahajournals.org/content/3/4/406

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/